Ovarian function suppression with the gonadotrophin-releasing hormone (GnRH) analogue goserelin in premenopausal advanced breast cancer

E. Bajetta, L. Celio, N. Zilembo, A. Bono, D. Galluzzo, M. G. Zampino, A. Longhi, L. Ferrari, R. Buzzoni

Research output: Contribution to journalArticle


Aims and background: Goserelin is a gonadotrophin-releasing hormone (GnRH) analogue that induces the suppression of gonadal steroidogenesis, and it could therefore be a medical alternative to irreversible surgical castration. We report the clinical and endocrine results from 40 goserelin-treated premenopausal patients with advanced breast cancer. Methods: A depot formulation of the drug (3.6 mg s.c.) was administered fortnightly for the first 4 doses, and monthly thereafter. Gonadotrophins and estradiol (E2) levels were measured before and at specific times during the treatment. Results: Objective responses were observed in 17 of the 38 evaluable patients (45%), six of whom achieved complete remission. The best responses were observed on soft tissues (65%). Castration E2 levels were achieved in all of the patients. Conclusions: Our results confirm that goserelin is as effective as surgical oophorectomy in premenopausal advanced breast cancer.

Original languageEnglish
Pages (from-to)28-32
Number of pages5
Issue number1
Publication statusPublished - 1994



  • breast cancer
  • GnRH analogue
  • medical castration

ASJC Scopus subject areas

  • Cancer Research

Cite this